OncoMatch/Clinical Trials/NCT06151080
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
Is NCT06151080 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Lenalidomide combined with G-CHOP (LO CHOP) for dlbcl - diffuse large b cell lymphoma.
Treatment: Lenalidomide combined with G-CHOP (LO CHOP) — To evaluate the efficacy and adverse effects of lenalidomide combined with G-CHOP(LO-CHOP) in the treatment of newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
ANC ≥1.0 × 10^9/L, PLT ≥100 × 10^9/L, HGB ≥80 g/L; if myeloma involved: ANC ≥0.75 × 10^9/L, PLT ≥50 × 10^9/L, HGB not required
Kidney function
serum CR ≤2.0 × ULN (unless caused by lymphoma)
Liver function
serum bilirubin ≤2.0 × ULN, serum ALT and AST ≤2.5 × ULN (unless caused by lymphoma)
Cardiac function
Left ventricular ejection fraction (LVEF) was less than 45%
Normal major organ function: liver function: serum bilirubin ≤2.0 × ULN, serum ALT and AST ≤2.5 × ULN, renal function: serum CR ≤2.0 × ULN; (unless caused by lymphoma) Absolute neutrophil count (ANC)≥1.0 × 10^9 l, platelet count (PLT)≥100 × 10^9 L, hemoglobin content (HGB)≥80 g L, if myeloma was involved, ANC ≥0.75 × 10^9 L, platelet count (PLT)≥50 × 10^9 L, HGB content (HGB) was not required. Left ventricular ejection fraction (LVEF) was less than 45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify